EMERALD Study for relutragine from Praxis

Kelly Del Real, Director of Patient Strategy at Praxis and a mother of a child with a DEE, presents an overview of the EMERALD Study for relutragine. Relutragine is a small molecule sodium channel modulator that only targets over-active neurons. The EMERALD Study is a Phase 3 Decentralized Clinical Trial that is enrolling anyone who has one of several DEEs, including STXBP1-RD. Participation in this study can be at home, without the need to visit a clinic.

Study website: www.resiliencestudies.com/emerald

ClincalTrials.gov page: https://clinicaltrials.gov/study/NCT07010471